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Despite numerous attempts over many years to develop an HIV vaccine based on classical strategies,
none has convincingly succeeded to date. A number of approaches are being pursued in the field,
including building upon possible efficacy indicated by the recent RV144 clinical trial, which combined
two HIV vaccines. Here, we argue for an approach based, in part, on understanding the HIV envelope
spike and its interaction with broadly neutralizing antibodies (bnAbs) at the molecular level and using
this understanding to design immunogens as possible vaccines. BnAbs can protect against virus chal-
lenge in animal models, and many such antibodies have been isolated recently. We further propose
that studies focused on how best to provide T cell help to B cells that produce bnAbs are crucial
for optimal immunization strategies. The synthesis of rational immunogen design and immunization
strategies, together with iterative improvements, offers great promise for advancing toward an HIV
vaccine.The HIV Vaccine Problem: Why Have Past Approaches
to Develop an HIV Vaccine Failed?
It is nearly 30 years since HIV was identified as the causative
agent of AIDS, and yet no vaccine is approaching licensure.
This is intensely disappointing. It is due partly to the fact that
the process of vaccine development typically takes a long
time period, partly to the failure of classical viral vaccination
strategies when applied to HIV, and partly to the many barriers
to immune recognition evolved by the virus. For acute viruses
such as smallpox and polio, natural infection leads to a large
fraction of individuals who are immune to reinfection. Hence,
vaccination strategies to mimic natural infection without
adverse sequelae can be designed. For persistent viruses,
immunity to reinfection cannot be readily determined, but
nevertheless, in some cases such as human papillomavirus
(HPV), a relatively straightforward approach in which vaccines
elicit neutralizing IgG is effective (Day et al., 2010). However,
for the highly variable retrovirus HIV, the classical vaccination
strategies have failed, and it is worth considering why this is
the case.396 Cell Host & Microbe 12, October 18, 2012 ª2012 Elsevier Inc.Immunogen Design Strategies Have Failed to Elicit
Broadly Neutralizing Antibody Responses
to Circulating HIV
As for other viruses, animal model studies, including the
macaque, provide an abundance of evidence for protection
against HIV or SHIV (chimeric HIV/SIV with envelope (Env) of
HIV) challenge by neutralizing antibodies. However, to protect
against the huge diversity of global circulating HIVs, the neutral-
izing antibody response should be broad, and traditional vaccine
approaches have failed to induce such a response. We note that
although there are reports of some degree of antibody protection
in the absence of serum-neutralizing antibodies, including the
RV144 trial, the protection is generally not particularly strong,
and so we focus here on neutralizing antibodies.
Live Attenuated and Killed Viruses: Direct
Pathogen Mimicry
Many highly successful vaccines rely on direct mimicry of
the pathogen. Live-attenuated viruses (e.g., measles, mumps,
yellow fever), inactivated viruses (e.g., poliovirus), or virus-like
particles (e.g., HPV) have been used to imitate natural infection
Figure 1. Structure and Antibody
Recognition of the HIV Envelope Spike
The molecule is a heterotrimer of composition
(gp120)3 (gp41)3. Gp41 is a transmembrane pro-
tein, and gp120 is the receptor molecule for CD4
and CCR5 (or CXCR4). The model (Schief et al.,
2009) is adapted from a cryo-electron tomo-
graphic structure of the HIV trimer (Liu et al., 2008).
The crystal structure of the b12-bound monomeric
gp120 core (red) has been fitted into the density
map (Zhou et al., 2007). Glycans are shown in
purple. The CD4 binding site is shown in yellow.
The approximate locations of the epitopes tar-
geted by existing bnMAbs are indicated with
arrows, and the number of MAbs targeting each
epitope is shown in red boxes. A small selection of
bnMAbs targeting each epitope is included.
Cell Host & Microbe
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these approaches have been unsuccessful for HIV vaccine
development (Burton et al., 2005; Kong and Sattentau, 2012;
Kwong et al., 2011; Overbaugh and Morris, 2012; Pantophlet
and Burton, 2006; Verkoczy et al., 2011; Wyatt and Sodroski,
1998). The challenges in this approach are largely related to
the properties of the HIV envelope (Env) spike, which is a heter-
odimer of the glycoproteins gp120 and gp41 that forms trimers
on the virion surface and mediates entry by binding to CD4 and
CCR5 or CXCR4 on the target cell surface. First, the variable
regions of the functional HIV Env trimer spike (Figure 1), the
trimer being the sole target of neutralizing antibodies, are typi-
cally immunodominant relative to conserved regions of the
spike and, thus, the neutralizing antibody response against
HIV is generally highly strain specific. Second, the extraordinary
variability in antigenic regions of the Env spike means that the
number of circulating HIV strains is extremely high and that
conventional concepts of viral serotypes are rendered irrele-
vant. Third, because of the instability of the HIV spike, most viral
particle-based vaccines tend to express immunodominant,
nonfunctional forms of Env on the virion surface (Poignard
et al., 2003), which favor the induction of nonneutralizing anti-
bodies (Crooks et al., 2007). Fourth, there is a relatively low
copy number of Env molecules on HIV particles, leading to
expectations of rather poor activation of B cells as compared
to viruses with dense Env coating, such as influenza. Fifth, other
complicating factors, such as the induction of antibodies
against cellular proteins, have contributed to difficulties with
viral particle-based immunogens (Chan et al., 1992; Crooks
et al., 2007; Hammonds et al., 2005). Although a number of
strategies to overcome these hurdles have been employed,
including pseudotyping HIV with heterologous envelopes (KuateCell Host & Microbe 12,et al., 2006; Marsac et al., 2002) and
generating VLPs with cleavage-defective
or disulfide-shackled Env to prevent
gp120-gp41 dissociation (Crooks et al.,
2007), none of these approaches have
yet induced potent heterologous anti-
body responses in nonhuman primate
(NHP) models. Finally, it should be noted
that, because of the risk of mutation and
reversion to a pathogenic form, the useof live attenuated HIV vaccines in humans raises formidable
safety and liability issues.
Subunit Vaccines: Recombinant Env
Using the same paradigm that formed the basis for successful
development of a vaccine against hepatitis B, initial attempts
to generate a protective vaccine against HIV focused on the elic-
itation of Env-specific humoral immune responses using gp120
subunit immunogens. Unfortunately, the results of clinical trials
indicated that the antibodies elicited by monomeric gp120 failed
to neutralize HIV primary isolates, prevent HIV infection, reduce
viral loads, or delay disease progression (Flynn et al., 2005;
Pitisuttithum et al., 2006). Therefore, over the ensuing years,
more attention has been focused on the generation of soluble,
recombinant trimers as immunogens to better simulate the
structure of the native HIV Env spike. Indeed, given that antibody
binding to the trimer is both necessary and sufficient for neu-
tralization (Pantophlet et al., 2009; Parren and Burton, 2001;
Roben et al., 1994; Sattentau and Moore, 1995; Wallace and
Stamatatos, 2009; Yang et al., 2006), a recombinant native trimer
represents an excellent starting point for the elicitation of bnAb
responses. However, the instability of the functional HIV spike
has presented challenges to the development of recombinant
trimers that mimic the structure of the native spike (Phogat and
Wyatt, 2007). Various strategies, including the introduction of
disulfide bonds to covalently link gp120 and gp41, the deletion
of the furin cleavage site in gp160 so that furin-mediated prote-
olysis to yield noncovalently linked gp120 and gp41 subunits
does not occur, and the incorporation of trimerization motifs
into the gp41 ectodomain, have been employed to stabilize
recombinant trimers (Phogat and Wyatt, 2007). However, none
of the recombinant trimers developed to date display antigenic
profiles that truly mimic the native HIV spike, and theseOctober 18, 2012 ª2012 Elsevier Inc. 397
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mentally improved relative to those elicited by monomeric
gp120 (Grundner et al., 2005; Kang et al., 2009; Li et al., 2005).
As for viral particle-based vaccines, immunization with these
constructs has resulted in the elicitation of predominantly non-
neutralizing or strain-specific antibody responses (see above).
Immunogens Based on the Epitopes Recognized by
bnAbs
A significant fraction of HIV-infected individuals develop broadly
neutralizing responses over time (Binley et al., 2008; Doria-Rose
et al., 2009; Gray et al., 2009, 2011; Li et al., 2006; Sather et al.,
2009; Simek et al., 2009; Stamatatos et al., 2009), including
some ‘‘elite neutralizers,’’ who display outstanding serum neu-
tralization potency (Simek et al., 2009). Mapping of serum
responses in broad neutralizers shows the targeting of a rela-
tively small number of broadly neutralizing epitopes on Env,
such as the CD4 binding site (CD4bs), glycan-dependent
epitopes, quaternary structure dependent epitopes, and the
membrane proximal external region (MPER) (Gray et al., 2009;
Stamatatos et al., 2009; Walker et al., 2010). Broadly neutralizing
monoclonal antibodies (bnMAbs) define these epitopes more
precisely (Figure 1) and suggest the possibility of incorporating
the epitopes into more favorable presentations than current
Env preparations, such as engineered Env molecules or scaf-
folds or multivalent glycan presentations (Burton, 2002; Schief
et al., 2009). Such approaches have, however, been unsuccess-
ful for a number of reasons that probably include the following:
(1) Until very recently, only a few bnMAbs were available so
that, for instance, all attempts to design immunogens based
on the CD4bs were guided by the sole anti-CD4bs bnMAb,
b12. The remarkable discoveries of many more potent anti-
CD4bs bnMAbs in the last 2 years may renew opportunities in
this area (Corti et al., 2010; Falkowska et al., 2012; Scheid
et al., 2011; Wu et al., 2010; Wu et al., 2011), although there
are still concerns that unusually precise directional targeting to
the CD4bs epitope may be required (Chen et al., 2009). (2)
Targeting the glycan epitope recognized by the bnMAb 2G12
presents problems in terms of the special domain-exchanged
configuration of this antibody (Calarese et al., 2003), which
was thought necessary for recognition of the glycan shield that
surrounds gp120. However, new data bring this requirement
into question and may offer new strategies for vaccine targeting
either of the glycan shield or of penetrating the shield via a mixed
protein-glycan immunogen (Pejchal et al., 2011; Walker et al.,
2011a). (3) Continuous epitopes on the MPER of Env gp41
(Buzon et al., 2010; Morris et al., 2011; Muster et al., 1993;
Salzwedel et al., 1999; Zhu et al., 2011; Zwick et al., 2001) offer
potentially attractive vaccine targets, and some success has
been achieved in eliciting strong responses to relevant peptides
derived from this region in one or more viral conformations
(Correia et al., 2010, 2011; Ofek et al., 2010). However, the prox-
imity of the epitopes to the membrane may offer special
problems in eliciting MPER antibodies. In addition, MPER anti-
bodies have been associated with autoreactivity (Haynes
et al., 2005a, 2005b), and this argued to be a problem in inducing
such antibodies. However, the recent description of a potent
MPER bnMAb that shows no autoreactivity (Huang et al.,
2012) suggests that autoreactivity may not be the overarching
problem envisaged earlier.398 Cell Host & Microbe 12, October 18, 2012 ª2012 Elsevier Inc.In summary, the challenge for epitope-based vaccine design is
that only broadly conserved and exposed epitopes are suitable
for vaccine targeting, but these epitopes, in their natural context,
tend to elicit poor antibody responses. When bnAb responses
are elicited, the corresponding bnMAbs tend to have unusual
features such as high levels of somatic mutations, insertions/
deletions, long CDRH3 loops, posttranslational modifications,
polyreactivity, and rare structural motifs such as domain
exchange.
Overall, these observations indicate that successful vaccina-
tion may require considerable ingenuity in immunogen design
and immunization protocols that go far beyond current norms.
Sterilizing Immunity, or Close to It, Will Likely Be
Necessary for Protective Immunity against HIV
The ultimate goal of vaccination is to provide protective immu-
nity against disease. For most successful vaccines (e.g.,
measles, polio, smallpox, etc.), protection against disease can
be achieved in the absence of sterilizing immunity. Indeed,
under most circumstances, immunization does not induce suffi-
ciently high and persistent titers of antibodies to prevent infec-
tion (Plotkin, 2008). For example, in the case of measles, very
high antibody titers of R1,000 mIU/ml are generally required
to protect against infection, but titers of R200 mIU/ml are
sufficient to protect against disease (Chen et al., 1990). In
contrast, for HIV, because of the establishment of persistent
latent infection in which viral DNA is integrated into host
genomic DNA, the window of opportunity to clear virus may
close permanently once a pool of latently infected cells is in
place (Haase, 2010, 2011), although the results of Picker and
colleagues, as noted below, do suggest that, in some cases,
a cellular response can control and suppress virus replication
to very low levels (Hansen et al., 2011).
Cellular Immune Responses Generally Do Not Prevent
Acquisition of Infection
It is clear from several animal studies that vaccines that induce
only CD8+ T cells (also known as cytotoxic T lymphocytes
[CTLs]), and no virus-specific antibodies, can efficiently control
subsequent challenge with a viral pathogen, as shown for
lymphocytic choriomeningitis virus (LCMV) (Klavinskis et al.,
1989), influenza virus (Ulmer et al., 1993), and respiratory syncy-
tial virus (RSV) (Kulkarni et al., 1995). However, these ‘‘CTL-only
vaccines’’ typically prevent severe disease, but not infection
itself, and can allow significant viral replication. Indeed, recent
studies suggested that cellular responses alone could not block
acquisition of SIV infection in the macaque model; the inclusion
of Env in the vaccine was required for complete prevention of
infection (Barouch et al., 2012). In the context of HIV, CTL
vaccines might be expected to permit considerable viral seeding
of lymphoid tissue during acute infection and the establishment
of a significant pool of latently infected cells with concomitant
adverse consequences (Liu et al., 2009). However, recent
studies (Hansen et al., 2011) have described a Cytomegalovirus
(CMV) vector-based SIV vaccine that appears to function via
CD8+ T cell immunity and restricts SIV replication to very low
levels in a significant fraction of vaccinated animals. The induc-
tion of such a response could contribute to vaccine protection
against HIV and serve as a second line of defense to contain
Figure 2. The Evolving Definition of Broad and Potent Neutralization
of HIV
For a long period, MAbs such as b12, 2G12, and 4E10 were the most potent
and the most broadly available. MAbs PG9 (Walker et al., 2009) and VRC01
(Wu et al., 2010) were discovered and shown to be broad and about an order of
magnitude more potent. Later, MAbs PGT121 and PGT128 (Walker et al.,
2011a) were shown to be even more potent. The engineered mAb NIH45-
46G54W is still more potent and broad (Diskin et al., 2011). Enhanced neutral-
ization potency, if translated into enhanced protective ability, is important,
since it reduces the level of antibody that should be induced by a vaccine.
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fully prevent initial infection of target cells.
What Goals Should Be Set to Move toward a Rationally
Designed HIV Vaccine?
Given the challenges identified above, we propose a number
of goals that should be targeted in order to move toward an
HIV vaccine based on neutralizing antibody, B cell, and CD4+
T cell studies.
Fully Define the Antibodies and Epitopes Associated
with Broad Neutralization of HIV
NAbs are the best correlate of protection for many viral vaccines
(Amanna and Slifka, 2011; Plotkin, 2010), and for HIV, nAbs have
been shown to provide robust protection against mucosal
challenge in the macaque model as described above. Therefore,
a major goal of HIV vaccine research should be the discovery of
immunogens and immunization strategies that can elicit nAbs, or
more specifically broadly nAbs (bnAbs), given high sequence
variation in HIV Env. As part of this discovery effort, it is important
to fully map the landscape of bnAb recognition of the HIV Env
spike, the sole target of nAbs, as described above. The recent
generation of larger numbers of potent bnMAbs (Figure 2) using
single B cell technologies (Burton et al., 2012; Corti et al., 2010;
Haynes et al., 2012; Klein et al., 2012; Kong and Sattentau, 2012;
Moir et al., 2011; Overbaugh and Morris, 2012; Scheid et al.,
2009, 2011; Tiller et al., 2008; Walker et al., 2011a; Wu et al.,
2010, 2011) has begun to reveal new bn epitopes and defined
‘‘sites of vulnerability’’ (Kwong and Wilson, 2009) on the Env
spike with much greater accuracy (Figure 1). However, ideally
one would like to generate and characterize enough bnMAbs
with enough redundancy in epitope recognition to be confident
that HIV Env bnAb space has been fully covered. A full com-
plement of bn epitopes can then be exploited for generating
immunogens with optimal precision.
The bnMAbs are, in themselves, valuable tools for guiding
vaccine discovery. The isolation of multiple bnMAbs that recog-nize similar epitopes is revealing the extent to which certain
structural features (e.g., long CDRH3s, polyreactivity, domain
exchange, high levels of somatic hypermutation, posttransla-
tional modifications, etc.) are required for recognition. For
example, recently described CD4bs-directed antibodies exhibit
remarkably broad and potent activity but, unlike b12, do not
require a long CDRH3 for gp120 binding (Scheid et al., 2009;
Wu et al., 2010; Zhou et al., 2010). Therefore, the elicitation of
bnMAbs against the CD4bs may not necessitate the design of
immunization protocols that aim to preferentially select anti-
bodies with long CDRH3s. Also, the isolation of multiple bnMAbs
against single antigenic regions helps delineate whether the use
of certain germline genes can facilitate epitope recognition. In
support of this notion, it has been suggested that the use of
two closely related VH germline genes (VH1-2*02 and VH1-46),
which encode the variable regions of Abs that contribute to
immunogen specificity, allows for a conserved mode of epitope
recognition by certain CD4bs-directed bnMAbs (Scheid et al.,
2011; West et al., 2012; Wu et al., 2011, 2012; Zhou et al.,
2010). The bnMAbs described to date have high levels of
somatic hypermutation (Scheid et al., 2011; Walker et al.,
2009, 2011a; Wu et al., 2010), a process in which mutations
are introduced into the antibody variable regions to generate
diversity. This may dictate that immunogens and/or immuniza-
tion protocols should be designed to increase antibody affinity
maturation (e.g., adjuvants, viral vectors, etc.). Alternatively,
the high levels of somatic hypermutation may simply reflect the
outcome of chronic antigen stimulation resulting from long-
term HIV infection. Indeed, anti-Env Abs from chronic infection
in general, whether neutralizing or not, tend to have high levels
of somatic hypermutation (Barbas et al., 1993; Breden et al.,
2011; Scheid et al., 2009). Therefore, it may be possible to
generate immunogens and/or immunization protocols that
shortcut the route to generation of bnAbs and result in antibodies
with much less somatic hypermutation.
Determine the bnMAbs that Provide the Best Protection
against SHIV in the NHP Model
Clearly, the property of antibodies that interests most in terms of
vaccine discovery is protection in humans. Neutralization is
simply a property that can be readily measured in vitro and
which has a good pedigree for qualitative prediction of protec-
tion against SHIV in the NHP model and against many other
viruses in humans. Ideally, we would like to correlate protection
in humans with neutralization assays, but this likely requires
either large-scale human passive immunization studies or
a vaccine that has clear efficacy, although superinfection and
mother-to-child transmission studies may also provide useful
correlative data (Blish et al., 2008; Chohan et al., 2010; Dickover
et al., 2006; Guevara et al., 2002; Lathey et al., 1999; Scarlatti
et al., 1993a, 1993b; Smith et al., 2006). The best animal model
is probably SHIV infection in macaques, and titration of protec-
tion for several of the newer bnMAbs in high- and low-dose
SHIV vaginal challenge models is important to better define
the relationship between protection and both in vitro neutraliza-
tion and antibody specificity. Finally, investigation of passive
protection in animal models expressing human antibody reper-
toires, e.g., the humanized BLT (bone marrow/liver/thymus)
mouse (Brainard et al., 2009; Wheeler et al., 2011), is highly
desirable.Cell Host & Microbe 12, October 18, 2012 ª2012 Elsevier Inc. 399
Figure 3. Model for Native Env
Glycosylation
Following removal of terminal a-linked glucose
residues in the endoplasmic reticulum (ER), folded
glycoproteins contain exclusively oligomannose
glycans. During transit through the ER, interme-
diate compartment, and cis-Golgi apparatus,
Mana1-2Man termini are removed by man-
nosidases to yield Man5GlcNAc2. However, the
oligomannose cluster intrinsic to monomeric
gp120 limits glycan processing on both mono-
meric and oligomeric gp120. The steric conse-
quences of trimerization further limit Mana1-2Man
trimming, leading to an additional ‘‘trimer-associ-
ated’’ population of Man5–9GlcNAc2. The
exposed Man5GlcNAc2 glycans on gp120 that
passage through the full extent of the Golgi
apparatus and trans-Golgi network to the plasma
membrane are processed to form complex-
type glycans. However, envelope glycoprotein
that does not follow this route to the plasma
membrane—a notable feature of some pseudo-
viral production systems—is characterized by
an elevated abundance of Man5GlcNAc2 and
reduced furin cleavage (Crooks et al., 2011). Thus the intrinsic mannose patch, which includes the 2G12 epitope, persists from the earliest stages of glycan
processing, while other elements of the glycan shield exhibit variably processed glycans depending on oligomerization state and, at least in the case of
pseudoviral gp160/gp120, cellular trafficking (adapted from Bonomelli et al., 2011).
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Preparation that Mimics the Antigenic Profile of the
Functional Env Spike
The functional HIV Env spike is the sole target of neutralizing
antibodies, as discussed above. Remarkably, because of the
instability of the spike, it is likely that no immunization with
pure native spikes has yet been carried out; infectious virions
express multiple Env species so that even natural infection pres-
ents a complex mix of Env molecules to the immune system
(Moore et al., 2006; Poignard et al., 2003). A number of strategies
to generate a pure stable Env preparation that mimics the
antigenic profile of the functional Env spike are ongoing. First,
cocrystallization of recombinant Env trimers with a variety of
bnMAbs is being attempted and hopefully will eventually
generate a high-resolution structure that will allow for rational
approaches to stabilizing a recombinant trimer. Second, the
resolution and methodologies of cryo-electron microscopy
(cryo-EM) and cryo-electron tomography are being enhanced
and may similarly provide enough molecular detail to allow the
rational design of stable trimers (Liu et al., 2008; Mao et al.,
2012). Third, various molecular display and selection strategies,
including positive selection with bnMAbs and negative selection
with nonneutralizing Abs, are being studied. Fourth, gp120/gp41
sector analyses (Dahirel et al., 2011) are being used to identify
potential gp120-gp41crosslinking stabilization sites. It should
be noted, though, that even if stable trimer immunogens can
be designed, engineering strategies will still likely be required
to dampen responses to immunodominant variable regions of
the Env trimer molecule to favor elicitation of bNAb responses.
Define Glycosylation on the Env Trimer
Approximately half of the molecular mass of gp120 is comprised
of N-linked glycans that shield the protein backbone. Con-
sidering that these carbohydrate structures are critical for Env
folding, binding to lectin receptors that may mediate transmis-
sion, antigenicity, and immunogenicity, a complete under-
standing of the identity and heterogeneity of glycans expressed
on native trimers may be crucial for the development of HIV400 Cell Host & Microbe 12, October 18, 2012 ª2012 Elsevier Inc.vaccine candidates. Although the glycosylation profiles of re-
combinant Env proteins and native viral Env have been analyzed
by mass spectrometry (Bonomelli et al., 2011; Doores et al.,
2010; Go et al., 2008, 2009, 2011; Mizuochi et al., 1988; Zhu
et al., 2000), a full definition of site-specific glycosylation on
these Envs has not yet been possible. Such an analysis would
provide insight into the role of specific glycans in forming or
shielding antibody epitopes in the context of gp120 monomers
and native HIV Env trimers, which may inform immunogen
design efforts. Of note, recent studies suggest that functional
Env trimers are substantially resistant to mannosidase, which
hydrolyzes mannose glycans, and express a higher abundance
of oligomannose glycans that are often found on monomeric
gp120 (Bonomelli et al., 2011; Doores et al., 2010; Eggink
et al., 2010) (Figure 3). Additionally, even the same recombinant
gp120—when expressed in different, commonly used cell
lines—can show widely varying abundances of oligomannose-
type glycans as well as exhibiting different varieties of
complex-type glycans (Raska et al., 2010). These differences
in glycan composition are of direct immunological significance:
enzymatic modification of gp120 glycans (Banerjee et al.,
2009), or even direct occlusion of gp120 glycans by protective
lectin (Banerjee et al., 2012), can dramatically alter the antibody
response to gp120. These observations, coupled with the fact
that recombinant gp120 has been used extensively in animal
studies and human vaccine trials with very limited success,
necessitate that consideration be given to the impact of differing
glycosylation patterns on the antigenicity and immunogenicity of
Env. In contrast to the variation seen between expression
systems, the overall glycosylation pattern of native envelope
glycoproteins derived from peripheral blood mononuclear cells
(PBMCs), even from highly divergent HIV clades, is remarkably
well conserved (Bonomelli et al., 2011).
Determine Where, When, How, and Which HIV Antigens
Are Engaged by B Cells
Understanding how the immune system recognizes and pro-
cesses viral antigens for durable humoral immunity is of
Cell Host & Microbe
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now clear that B cells can encounter and respond to antigen
through many different mechanisms depending on the nature
and size of the antigen itself, as well as on the cellular context
and location in which antigen presentation occurs. For example,
within the context of the lymph node, small soluble antigens
access the B cell follicle, the primary site where B cell activation
occurs, through a follicular conduit system (Roozendaal et al.,
2009), whereas particulate antigens, such as viruses and large
immune complexes, are captured by subcapsular sinus macro-
phages for presentation to follicular B cells (Gonzalez et al.,
2011). In the case of HIV Env, particularly considering the
dramatic instability of the native Env spike, it is unclear which
Env antigens are presented to B cells and how and where these
encounters occur after infection. For example, how often, if ever,
do B cells engage functional Env spikes in vivo? Additionally,
what are the predominant Env species presented to B cells:
monomeric gp120, gp41, proteolyzed Env fragments, and/or un-
cleaved gp160? Although the above questions concern viral Env
in the context of HIV/SIV infection, an equally important issue is
how soluble vaccine immunogens are processed and presented
to B cells. The answers to these questions will have important
implications for the design of improved HIV vaccine candidates.
We believe these questions can be addressed in the macaque
model and in mice, particularly in bnMAb knockin mice.
Explain How and Why a Subset of HIV-Infected
Individuals Makes Potent bnAb Responses
A series of studies (Sather et al., 2009; Simek et al., 2009; Stama-
tatos et al., 2009; van Gils et al., 2009) have shown that 10%–
30%of HIV-infected donors developmoderate to potent broadly
neutralizing serum responses over time, providing support for
the notion that bnAbs can be elicited in humans and providing
a window into how to elicit such responses. Although serum-
mapping experiments (Binley et al., 2008; Gray et al., 2009,
2011; Li et al., 2007, 2009; Mikell et al., 2011; Moore et al.,
2011; Stamatatos et al., 2009; Walker et al., 2010) have largely
defined the antibody specificities that mediate broad serum
neutralization, there is currently limited information on how and
why broad responses develop within select individuals. A few
longitudinal studies (Euler et al., 2012; Gray et al., 2011; Sather
et al., 2009; van Gils et al., 2009) have examined the factors
associated with the development of breadth, and although there
are some inconsistencies, it has been suggested that broad
neutralization correlates with time postinfection, plasma viremia
levels, CD4+ T cell count at the viral set point, and binding avidity
to the envelope protein. In a recent longitudinal study (Gray et al.,
2011), breadth was found to emerge 2 years postinfection and
plateaued at year four, which corroborates earlier estimates
that bnAbs develop after 1–3 years (Gray et al., 2011; Sather
et al., 2009; Stamatatos et al., 2009; van Gils et al., 2009). While
all of these studies have provided valuable insight into the factors
associated with the development of bnAbs, more extensive
longitudinal studies (e.g., isolation of mAbs and viral Envs from
serial time points) in both humans and NHP models will be
required to understand the evolution and maturation of broad
responses. A major question is the relative contribution of the
virus and the host immune system to the evolution of these
responses. Key issues include the influence of the founder virus,
the possibility of viral motifs associated with broad neutraliza-tion, clinical correlates of broad neutralization, and the roles of
B cell dysfunction and CD4+ T cell help in developing bnAb
responses. Antibody deep sequencing of donors from whom
bnMAbs have been isolated may shed light on how bnAb
responses evolve over time (Wu et al., 2011). Of interest, it is ex-
pected that deep sequencing methods that maintain correct
pairing of the heavy and light chains that comprise antibodies
will become available in the near future to allow for functional
characterization of antibody responses. The unexpected obser-
vation of the development of a highly potent bnAb response in
a SHIV-infected macaque only 40 weeks postinfection (Walker
et al., 2011b) suggests that the role of the infecting virus and
the genetics of the host in bnAb responses could be readily ad-
dressed in NHP studies. Of note, retrospective, nested case-
controlled studies that utilize systems biological approaches to
identify early signatures that correlate with and predict the later
development of bnAbs should be useful in providing insights
about the mechanisms that control bnAb induction (Querec
et al., 2009).
Develop Model Systems for Immunogen Evaluation
A classical initial approach to immunogen evaluation is to use
serum antibody responses in small animals, such as mice and
rabbits, as a ‘‘gatekeeper’’ measurement to determine whether
to proceed with the immunogen in humans. This approach may
be less appropriate for HIV, given some of the features of bnAbs
described above. An alternate approach is to take advantage of
our knowledge of bnMAbs to generate model systems that can
be used to evaluate immunogens and immunization strategies
for their ability to elicit bnAbs in as high-throughput manner as
possible prior to testing in humans. Anexample of such a strategy
is to create knockinmice that carry germline forms of the different
human bnMAbs. Themice could be used to screen awide variety
of Env antigens for their abilities to induce bnMAb+murineB cells
to enter germinal centers (GCs) where B cells proliferate and
develop and to mature into B cells producing fully active anti-
bodies. A comparison of B cells carrying germline and mutated
versions of bnMAbs could be used to determine whether an
antigen that initiates immunity from ‘‘naive’’ B cell receptors
(BCRs) also stimulates antibody secretion from somatically
mutated ‘‘mature’’ BCRs. Further examples of potentially inter-
esting model systems for high-throughput immunogen evalua-
tion include transgenic mice with human repertoires (Legrand
et al., 2009; Rathinam et al., 2011) and the mouse BLT model
(Brainard et al., 2009; Wheeler et al., 2011), as described above.
Another approach is to generate immunogens that bind to NHP
germline versions of bnMAbs, as well as the corresponding
mature human bnAbs, based on modeling studies and on library
selection. Determination of the molecular interactions between
germline NHP Abs and immunogen would allow iterative
improvement of the immunogens, which could then be investi-
gated as candidate vaccines in NHPs. Whether in knockin mice
or NHPs, it is anticipated that iterative cycles of vaccination
followed by analysis of B and CD4+ T cell responses to guide
redesign of immunogens and immunization strategies will be
needed to generate optimal vaccines.
Accurately Identify and Functionally Characterize
HIV/SIV-Specific T Follicular Helper Cells in Humans
T follicular helper (Tfh) cells are newly appreciated cells, distinct
from other CD4+ T cell subsets, that are specialized for B cellCell Host & Microbe 12, October 18, 2012 ª2012 Elsevier Inc. 401
Figure 4. T Follicular Helper Cells Are the CD4+ T Cells that Are
Required for Germinal Centers and Control B Cell Differentiation
within the GCs
Tfh cells provide different signals to B cells to control different B cell fates, such
as plasma cell (antibody secreting cell) differentiation, memory B cell differ-
entiation, death, or repeated rounds of somatic hypermutation and GC B cell
proliferation. Generation of high-affinity neutralizing antibodies is generally
a multistep, iterative process that is dependent on affinity maturation via
somatic hypermutation and extensive signaling from Tfh cells (Crotty, 2011).
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Perspectivehelp and are required for formation and maintenance of GCs
(Johnston et al., 2009; Nurieva et al., 2009; Yu et al., 2009;
Rolf et al., 2010; Victora et al., 2010). As such, Tfh cells are
almost certainly critical for the development of most neutraliz-
ing Abs, GCs, and memory B cell responses (Crotty, 2011)
(Figure 4). A substantial population of HIV-specific Tfh cells
is present in the lymph nodes of HIV-infected individuals
(Lindqvist et al., 2012). Interestingly, new SIV studies have found
that Tfh cells are abundant in SIV-infected macaques, and Tfh
cell abundance correlates with GC B cells frequencies (Hong
et al., 2012; Petrovas et al., 2012). Furthermore, Tfh cell
frequency positively correlates with both anti-SIV IgG quantity
and quality (Petrovas et al., 2012). These findings are consistent
with the potential importance of Tfh cells in anti-HIV bnAb devel-
opment. Therefore, it is critical to be able to identify and track
HIV-specific Tfh cells to (1) understand their role in the develop-
ment of bnAb responses in HIV-infected humans, (2) quantify
Tfh cells elicited by candidate HIV vaccines, and (3) understand
and manipulate Tfh cell functions in HIV-specific immune
responses.
Describe the Mechanisms of Tfh Cell Generation and
Identify Adjuvants that Optimally Elicit Tfh Cells and
Potent B Cell Responses in the Context of HIV Env
Immunization
The induction of Tfh cell differentiation is a mutifactorial process
that involves not only the optimal activation of dendritic cells
(DCs), in particular expression of the ligand ICOSL that medi-
ates optimal T cell activation by binding to ICOS on T cells
(see review by Luban [2012] in this issue of Cell Host & Microbe)
(Choi et al., 2011; Goenka et al., 2011), but also optimal activa-
tion of B cells to maintain Tfh cell responses. Yet, the ‘‘danger402 Cell Host & Microbe 12, October 18, 2012 ª2012 Elsevier Inc.signals’’ that are involved in the generation of Tfh cells remain
unclear (Crotty, 2012). The identification of these signals and
adjuvants may be critically important for rational vaccine
design. Therefore, it is crucial to determine the optimal signals
for Tfh cell induction in a multistep process, first by determining
factors that induce ICOSL and other Tfh signals on DCs and
B cells using in vitro screening, and then by validating Tfh
differentiation adjuvants in the context of candidate vaccines
in NHPs.
Determine the Relationships between Tfh Cell
Specificity and Anatomic Distribution for Control
of HIV/SIV
HIV infection is primarily a mucosally transmitted infection, and
studies of mucosal tissue immune responses are key. Therefore,
it is important to determine the anatomic locations of HIV-
specific Tfh cells in the context of natural infection and candidate
vaccines to determine their role in mediating systemic humoral
immunity and mucosal humoral immunity. An additional issue
is one of protein specificity of the CD4 T cell responses. It is likely
that the CD4 T cell responses need to be specific for epitopes
within gp41 or gp120 to provide appropriate help to Env-specific
B cells, given data from other viral infections (Sette et al., 2008).
However, it is possible that this is not the case, and responses
specific to the HIV structural protein Gag may be sufficient if
whole virions are the primary functional antigen. This again
goes to the overall issue of it currently being unknown in what
form B cells see functional Env spikes. To track HIV-specific
Tfh cells requires an improved knowledge base, as HLA class
II restricted HIV epitopes are insufficiently well mapped for
human (or NHP) population studies involving single-cell-level
analysis via class II tetramers that recognize antigen-specific
T cells.
Identify Effector Mechanisms of HIV-Specific CD4+ T
Cells and Define Their Role in Viral Control at the Portal
of Entry
After mucosal transmission creates small founder populations of
infected cells, local expansion at the portal of entry is necessary
to establish infection, which may offer a window of opportunity
for cellular immunity to prevent viral dissemination (Haase,
2011; Q. Li, L. Duan, M. Zeng, J.E. Voss, S. Pambuccian, L.
Shang, A.J. Smith, S. Wietgrefe, P.J. Southern, C.S. Reilly, P.J.
Skinner, M.L. Zupancic, J.V. Carlis, M. Piatak, Jr., D. Waterman,
R.K. Reeves, K. Masek-Hammerman, C.A. Derdeyn, H. Kohler,
S. Muller, J. Robinson, J.D. Lifson, D.R.B., R.P. Johnson, and
A.T. Haase, unpublished data). To address the role of early viral
containment through cellular adaptive immunity, cross-sectional
studies of blood, gut-associated lymphoid tissue (GALT), and
vaginal (cervix) biopsies in HIV elite controllers and individuals
with progressive disease should be carried out. Longitudinal
studies of NHP CD4+ and CD8+ T cell responses in tissue
compartments should first define the spatial correlation between
these cells and infected cells, and disease stage. Studies of the
early kinetics of the T cell responses in previously vaccinated,
acutely SIV-infected NHPs will allow determination of whether
an initial influx of virus- specific CD4+ T cells precedes robust
CTL responses and correlates with early containment (Kuma-
moto et al., 2011). Alternatively, CD4+ CTL may directly
contribute to containment of HIV infection (Soghoian et al.,
2012).
Figure 5. An Approach to HIV Vaccine Discovery
Molecular data on protective Abs (typically bnAbs), Env, and Ab-Env
complexes, should facilitate the generation of antigens presenting protective
epitopes. These antigens can then be formulated as immunogens and tested
in animals and humans. The characteristics of the protective Abs also provide
information on how they were generated that can be investigated in B and
CD4+ T cell studies, guiding both immunogen design and immunization
strategies. Gaps in our current knowledge suggest that iteration will be an
important part of the development of vaccine candidates, as indicated by the
feedback loops shown in the figure.
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PerspectiveBringing It All Together to Design Immunogens and
Immunization Strategies to Elicit Broadly Neutralizing
HIV Antibody Responses
Many immunogens have been designed and are under design
based on our current knowledge of the structure of the HIV
Env trimer and on our knowledge of the epitopes recognized
by bnMAbs (Forsell et al., 2009; Karlsson Hedestam et al.,
2008; Kwong et al., 2011, 2012; Mascola and Montefiori, 2010;
Schief et al., 2009; Walker and Burton, 2010). These immuno-
gens are being engineered in myriads of ways (Azoitei et al.,
2011; Correia et al., 2010, 2011; McLellan et al., 2011; Ofek
et al., 2010) and are based not only on immunogen interaction
with mature bnMAbs but also on interaction with the bnMAbs
in a germline configuration (Haynes et al., 2012; Xiao et al.,
2009). We expect that many of the new tools for analyzing
immune responses to immunization, such as systems biology,
antibody deep sequencing, and single B cell methods for anti-
body isolation, will be invaluable in providing a rich feedback
on the strengths and weaknesses of the immunogen designs
and immunization strategies. As the goals described above are
realized, we expect the information to be incorporated to further
improve the rational design strategy. We see one of the most
crucial rate-limiting steps in the whole process to be iterative
immunogen evaluation. Practical considerations appear to rule
out the ideal test subjects for such evaluation—humans—and
then the best candidates appear to be macaques or small
animals expressing human antibody repertoires.
In summary, the central hypotheses that we advocate are that
a successful HIV vaccine should elicit protective antibodies, andthat the combination of B cell and CD4+ T cell responses is
critical for the induction and long-term maintenance of vaccine
protection. We believe that it is crucial to define immunogens
and immunization regimens that induce protective B cell and
CD4+ T cell responses in preclinical models and thereby guide
product development strategies for a preventive human HIV
vaccine. We note that such a vaccine may well also need to
induce HIV-specific CD8+ T cell responses for maximal efficacy,
as considered elsewhere (Barouch and Korber, 2010; Johnston
and Fauci, 2007; McElrath and Haynes, 2010; Walker and
Burton, 2008;Watkins, 2008).We propose here integrated efforts
focused on two areas: (1) B cell and antibody research to guide
the development of immunogens and immunization regimes that
elicit protective HIV antibody responses, and (2) CD4+ T cell
research, taking advantage of key preliminary data to maximize
the T cell help offered to B cell responses through immunization
and to harness the direct antiviral activity of CD4+ T cells
(Figure 5). Overall, we view this as an extremely exciting period
in the field of HIV vaccine research and one that engenders
more hope than has been noted for a long time.
REFERENCES
Amanna, I.J., and Slifka, M.K. (2011). Contributions of humoral and cellular
immunity to vaccine-induced protection in humans. Virology 411, 206–215.
Azoitei, M.L., Correia, B.E., Ban, Y.E., Carrico, C., Kalyuzhniy, O., Chen, L.,
Schroeter, A., Huang, P.S., McLellan, J.S., Kwong, P.D., et al. (2011). Compu-
tation-guided backbone grafting of a discontinuous motif onto a protein
scaffold. Science 334, 373–376.
Banerjee, K., Andjelic, S., Klasse, P.J., Kang, Y., Sanders, R.W., Michael, E.,
Durso, R.J., Ketas, T.J., Olson, W.C., and Moore, J.P. (2009). Enzymatic
removal of mannose moieties can increase the immune response to HIV-1
gp120 in vivo. Virology 389, 108–121.
Banerjee, K., Michael, E., Eggink, D., van Montfort, T., Lasnik, A.B., Palmer,
K.E., Sanders, R.W., Moore, J.P., and Klasse, P.J. (2012). Occluding the
mannose moieties on human immunodeficiency virus type 1 gp120 with grif-
fithsin improves the antibody responses to both proteins in mice. AIDS Res.
Hum. Retroviruses 28, 206–214.
Barbas, C.F., 3rd, Collet, T.A., Amberg, W., Roben, P., Binley, J.M., Hoekstra,
D., Cababa, D., Jones, T.M., Williamson, R.A., Pilkington, G.R., et al. (1993).
Molecular profile of an antibody response to HIV-1 as probed by combinatorial
libraries. J. Mol. Biol. 230, 812–823.
Barouch, D.H., and Korber, B. (2010). HIV-1 vaccine development after STEP.
Annu. Rev. Med. 61, 153–167.
Barouch, D.H., Liu, J., Li, H., Maxfield, L.F., Abbink, P., Lynch, D.M., Iampietro,
M.J., SanMiguel, A., Seaman, M.S., Ferrari, G., et al. (2012). Vaccine protec-
tion against acquisition of neutralization-resistant SIV challenges in rhesus
monkeys. Nature 482, 89–93.
Binley, J.M., Lybarger, E.A., Crooks, E.T., Seaman, M.S., Gray, E., Davis, K.L.,
Decker, J.M., Wycuff, D., Harris, L., Hawkins, N., et al. (2008). Profiling the
specificity of neutralizing antibodies in a large panel of plasmas from patients
chronically infected with human immunodeficiency virus type 1 subtypes B
and C. J. Virol. 82, 11651–11668.
Blish, C.A., Dogan, O.C., Derby, N.R., Nguyen, M.A., Chohan, B., Richardson,
B.A., and Overbaugh, J. (2008). Human immunodeficiency virus type 1
superinfection occurs despite relatively robust neutralizing antibody
responses. J. Virol. 82, 12094–12103.
Bonomelli, C., Doores, K.J., Dunlop, D.C., Thaney, V., Dwek, R.A., Burton,
D.R., Crispin, M., and Scanlan, C.N. (2011). The glycan shield of HIV is
predominantly oligomannose independently of production system or viral
clade. PLoS ONE 6, e23521. http://dx.doi.org/10.1371/journal.pone.0023521.
Brainard, D.M., Seung, E., Frahm, N., Cariappa, A., Bailey, C.C., Hart, W.K.,
Shin, H.S., Brooks, S.F., Knight, H.L., Eichbaum, Q., et al. (2009). InductionCell Host & Microbe 12, October 18, 2012 ª2012 Elsevier Inc. 403
Cell Host & Microbe
Perspectiveof robust cellular and humoral virus-specific adaptive immune responses in
human immunodeficiency virus-infected humanized BLT mice. J. Virol. 83,
7305–7321.
Breden, F., Lepik, C., Longo, N.S., Montero, M., Lipsky, P.E., and Scott, J.K.
(2011). Comparison of antibody repertoires produced by HIV-1 infection, other
chronic and acute infections, and systemic autoimmune disease. PLoSONE 6,
e16857. http://dx.doi.org/10.1371/journal.pone.0016857.
Burton, D.R. (2002). Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2,
706–713.
Burton, D.R., Stanfield, R.L., andWilson, I.A. (2005). Antibody vs. HIV in a clash
of evolutionary titans. Proc. Natl. Acad. Sci. USA 102, 14943–14948.
Burton, D.R., Poignard, P., Stanfield, R.L., and Wilson, I.A. (2012). Broadly
neutralizing antibodies present new prospects to counter highly antigenically
diverse viruses. Science 337, 183–186.
Buzon, V., Natrajan, G., Schibli, D., Campelo, F., Kozlov, M.M., and
Weissenhorn, W. (2010). Crystal structure of HIV-1 gp41 including both fusion
peptide and membrane proximal external regions. PLoS Pathog. 6, e1000880.
http://dx.doi.org/10.1371/journal.pone.0016857.
Calarese, D.A., Scanlan, C.N., Zwick, M.B., Deechongkit, S., Mimura, Y.,
Kunert, R., Zhu, P., Wormald, M.R., Stanfield, R.L., Roux, K.H., et al. (2003).
Antibody domain exchange is an immunological solution to carbohydrate
cluster recognition. Science 300, 2065–2071.
Chan, W.L., Rodgers, A., Hancock, R.D., Taffs, F., Kitchin, P., Farrar, G., and
Liew, F.Y. (1992). Protection in simian immunodeficiency virus-vaccinated
monkeys correlates with anti-HLA class I antibody response. J. Exp. Med.
176, 1203–1207.
Chen, R.T., Markowitz, L.E., Albrecht, P., Stewart, J.A., Mofenson, L.M.,
Preblud, S.R., and Orenstein, W.A. (1990). Measles antibody: reevaluation of
protective titers. J. Infect. Dis. 162, 1036–1042.
Chen, L., Kwon, Y.D., Zhou, T., Wu, X., O’Dell, S., Cavacini, L., Hessell, A.J.,
Pancera, M., Tang, M., Xu, L., et al. (2009). Structural basis of immune evasion
at the site of CD4 attachment on HIV-1 gp120. Science 326, 1123–1127.
Chohan, B.H., Piantadosi, A., and Overbaugh, J. (2010). HIV-1 superinfection
and its implications for vaccine design. Curr. HIV Res. 8, 596–601.
Choi, Y.S., Kageyama, R., Eto, D., Escobar, T.C., Johnston, R.J., Monticelli, L.,
Lao, C., and Crotty, S. (2011). ICOS receptor instructs T follicular helper cell
versus effector cell differentiation via induction of the transcriptional repressor
Bcl6. Immunity 34, 932–946.
Correia, B.E., Ban, Y.E., Holmes, M.A., Xu, H., Ellingson, K., Kraft, Z., Carrico,
C., Boni, E., Sather, D.N., Zenobia, C., et al. (2010). Computational design of
epitope-scaffolds allows induction of antibodies specific for a poorly immuno-
genic HIV vaccine epitope. Structure 18, 1116–1126.
Correia, B.E., Ban, Y.E., Friend, D.J., Ellingson, K., Xu, H., Boni, E., Bradley-
Hewitt, T., Bruhn-Johannsen, J.F., Stamatatos, L., Strong, R.K., and Schief,
W.R. (2011). Computational protein design using flexible backbone remodel-
ing and resurfacing: case studies in structure-based antigen design. J. Mol.
Biol. 405, 284–297.
Corti, D., Langedijk, J.P., Hinz, A., Seaman, M.S., Vanzetta, F., Fernandez-
Rodriguez, B.M., Silacci, C., Pinna, D., Jarrossay, D., Balla-Jhagjhoorsingh,
S., et al. (2010). Analysis of memory B cell responses and isolation of novel
monoclonal antibodies with neutralizing breadth from HIV-1-infected individ-
uals. PLoS ONE 5, e8805. http://dx.doi.org/10.1371/journal.pone.0008805.
Crooks, E.T., Moore, P.L., Franti, M., Cayanan, C.S., Zhu, P., Jiang, P., de
Vries, R.P., Wiley, C., Zharkikh, I., Schu¨lke, N., et al. (2007). A comparative
immunogenicity study of HIV-1 virus-like particles bearing various forms of
envelope proteins, particles bearing no envelope and soluble monomeric
gp120. Virology 366, 245–262.
Crooks, E.T., Tong, T., Osawa, K., and Binley, J.M. (2011). Enzyme digests
eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env
trimers intact and viral infectivity unaffected. J. Virol. 85, 5825–5839.
Crotty, S. (2011). Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29,
621–663.
Crotty, S. (2012). The 1-1-1 fallacy. Immunol. Rev. 247, 133–142.404 Cell Host & Microbe 12, October 18, 2012 ª2012 Elsevier Inc.Cyster, J.G. (2010). B cell follicles and antigen encounters of the third kind. Nat.
Immunol. 11, 989–996.
Dahirel, V., Shekhar, K., Pereyra, F., Miura, T., Artyomov, M., Talsania, S.,
Allen, T.M., Altfeld, M., Carrington, M., Irvine, D.J., et al. (2011). Coordinate
linkage of HIV evolution reveals regions of immunological vulnerability. Proc.
Natl. Acad. Sci. USA 108, 11530–11535.
Day, P.M., Kines, R.C., Thompson, C.D., Jagu, S., Roden, R.B., Lowy, D.R.,
and Schiller, J.T. (2010). In vivo mechanisms of vaccine-induced protection
against HPV infection. Cell Host Microbe 8, 260–270.
Dickover, R., Garratty, E., Yusim, K., Miller, C., Korber, B., and Bryson, Y.
(2006). Role of maternal autologous neutralizing antibody in selective perinatal
transmission of human immunodeficiency virus type 1 escape variants. J. Virol.
80, 6525–6533.
Diskin, R., Scheid, J.F., Marcovecchio, P.M., West, A.P., Jr., Klein, F., Gao, H.,
Gnanapragasam, P.N., Abadir, A., Seaman, M.S., Nussenzweig, M.C., and
Bjorkman, P.J. (2011). Increasing the potency and breadth of an HIV antibody
by using structure-based rational design. Science 334, 1289–1293.
Doores, K.J., Bonomelli, C., Harvey, D.J., Vasiljevic, S., Dwek, R.A., Burton,
D.R., Crispin, M., and Scanlan, C.N. (2010). Envelope glycans of immunodefi-
ciency virions are almost entirely oligomannose antigens. Proc. Natl. Acad.
Sci. USA 107, 13800–13805.
Doria-Rose, N.A., Klein, R., Daniels, M., O’Dell, S., Nason, M., Lapedes, A.,
Bhattacharya, T., Migueles, S., Wyatt, R.T., Korber, B.T., et al. (2009). Breadth
of HIV-specific neutralizing activity in sera: clustering analysis and association
with clinical variables. J. Virol. 84, 1631–1636.
Eggink, D., Melchers, M., Wuhrer, M., van Montfort, T., Dey, A.K., Naaijkens,
B.A., David, K.B., Le Douce, V., Deelder, A.M., Kang, K., et al. (2010). Lack
of complex N-glycans on HIV-1 envelope glycoproteins preserves protein
conformation and entry function. Virology 401, 236–247.
Euler, Z., van den Kerkhof, T.L., van Gils, M.J., Burger, J.A., Edo-Matas, D.,
Phung, P., Wrin, T., and Schuitemaker, H. (2012). Longitudinal analysis of early
HIV-1-specific neutralizing activity in an elite neutralizer and in five patients
who developed cross-reactive neutralizing activity. J. Virol. 86, 2045–2055.
Falkowska, E., Ramos, A., Feng, Y., Zhou, T., Moquin, S., Walker, L.M., Wu, X.,
Seaman, M.S., Wrin, T., Kwong, P.D., et al. (2012). PGV04, an HIV-1 gp120
CD4 binding site antibody, is broad and potent in neutralization but does not
induce conformational changes characteristic of CD4. J. Virol. 86, 4394–4403.
Flynn, N.M., Forthal, D.N., Harro, C.D., Judson, F.N., Mayer, K.H., and Para,
M.F.; rgp120 HIV Vaccine Study Group. (2005). Placebo-controlled phase 3
trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J.
Infect. Dis. 191, 654–665.
Forsell, M.N., Schief, W.R., and Wyatt, R.T. (2009). Immunogenicity of HIV-1
envelope glycoprotein oligomers. Curr. Opin. HIV AIDS 4, 380–387.
Go, E.P., Irungu, J., Zhang, Y., Dalpathado, D.S., Liao, H.X., Sutherland, L.L.,
Alam, S.M., Haynes, B.F., and Desaire, H. (2008). Glycosylation site-specific
analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differ-
ences in glycosylation site occupancy, glycoform profiles, and antigenic
epitopes’ accessibility. J. Proteome Res. 7, 1660–1674.
Go, E.P., Chang, Q., Liao, H.X., Sutherland, L.L., Alam, S.M., Haynes, B.F., and
Desaire, H. (2009). Glycosylation site-specific analysis of clade C HIV-1 enve-
lope proteins. J. Proteome Res. 8, 4231–4242.
Go, E.P., Hewawasam, G., Liao, H.X., Chen, H., Ping, L.H., Anderson, J.A.,
Hua, D.C., Haynes, B.F., and Desaire, H. (2011). Characterization of glycosyl-
ation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry.
J. Virol. 85, 8270–8284.
Goenka, R., Barnett, L.G., Silver, J.S., O’Neill, P.J., Hunter, C.A., Cancro, M.P.,
and Laufer, T.M. (2011). Cutting edge: dendritic cell-restricted antigen presen-
tation initiates the follicular helper T cell program but cannot complete ultimate
effector differentiation. J. Immunol. 187, 1091–1095.
Gonzalez, S.F., Degn, S.E., Pitcher, L.A., Woodruff, M., Heesters, B.A., and
Carroll, M.C. (2011). Trafficking of B cell antigen in lymph nodes. Annu. Rev.
Immunol. 29, 215–233.
Gray, E.S., Taylor, N., Wycuff, D., Moore, P.L., Tomaras, G.D., Wibmer, C.K.,
Puren, A., DeCamp, A., Gilbert, P.B., Wood, B., et al. (2009). Antibody
specificities associated with neutralization breadth in plasma from human
Cell Host & Microbe
Perspectiveimmunodeficiency virus type 1 subtype C-infected blood donors. J. Virol. 83,
8925–8937.
Gray, E.S., Madiga, M.C., Hermanus, T., Moore, P.L., Wibmer, C.K., Tumba,
N.L., Werner, L., Mlisana, K., Sibeko, S., Williamson, C., et al; and the
CAPRISA002 Study Team. (2011). The neutralization breadth of HIV-1
develops incrementally over four years and is associated with CD4+ T cell
decline and high viral load during acute infection. J. Virol. 85, 4828–4840.
Grundner, C., Li, Y., Louder, M., Mascola, J., Yang, X., Sodroski, J., andWyatt,
R. (2005). Analysis of the neutralizing antibody response elicited in rabbits by
repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology 331,
33–46.
Guevara, H., Casseb, J., Zijenah, L.S., Mbizvo, M., Oceguera, L.F., 3rd,
Hanson, C.V., Katzenstein, D.A., and Hendry, R.M. (2002). Maternal HIV-1
antibody and vertical transmission in subtype C virus infection. J. Acquir.
Immune Defic. Syndr. 29, 435–440.
Haase, A.T. (2010). Targeting early infection to prevent HIV-1 mucosal trans-
mission. Nature 464, 217–223.
Haase, A.T. (2011). Early events in sexual transmission of HIV and SIV and
opportunities for interventions. Annu. Rev. Med. 62, 127–139.
Hammonds, J., Chen, X., Fouts, T., DeVico, A., Montefiori, D., and Spearman,
P. (2005). Induction of neutralizing antibodies against human immunodefi-
ciency virus type 1 primary isolates by Gag-Env pseudovirion immunization.
J. Virol. 79, 14804–14814.
Hansen, S.G., Ford, J.C., Lewis, M.S., Ventura, A.B., Hughes, C.M., Coyne-
Johnson, L., Whizin, N., Oswald, K., Shoemaker, R., Swanson, T., et al.
(2011). Profound early control of highly pathogenic SIV by an effector memory
T-cell vaccine. Nature 473, 523–527.
Haynes, B.F., Fleming, J., St Clair, E.W., Katinger, H., Stiegler, G., Kunert, R.,
Robinson, J., Scearce, R.M., Plonk, K., Staats, H.F., et al. (2005a). Cardiolipin
polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.
Science 308, 1906–1908.
Haynes, B.F., Moody, M.A., Verkoczy, L., Kelsoe, G., and Alam, S.M. (2005b).
Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum.
Antibodies 14, 59–67.
Haynes, B.F., Kelsoe, G., Harrison, S.C., and Kepler, T.B. (2012). B-cell-
lineage immunogen design in vaccine development with HIV-1 as a case
study. Nat. Biotechnol. 30, 423–433.
Hong, J.J., Amancha, P.K., Rogers, K., Ansari, A.A., and Villinger, F. (2012).
Spatial alterations between CD4(+) T follicular helper, B, and CD8(+) T cells
during simian immunodeficiency virus infection: T/B cell homeostasis, activa-
tion, and potential mechanism for viral escape. J. Immunol. 188, 3247–3256.
Huang, J., Ofek, G., Laub, L., Louder, M.K., Doria-Rose, N.A., Longo, N.S.,
Imamichi, H., Bailer, R.T., Chakrabarti, B., Sharma, S.K., et al. (2012). Broad
and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature.
Published online September 18, 2012. http://dx.doi.org/10.1038/nature11544.
Johnston, M.I., and Fauci, A.S. (2007). An HIV vaccine—evolving concepts. N.
Engl. J. Med. 356, 2073–2081.
Johnston, R.J., Poholek, A.C., DiToro, D., Yusuf, I., Eto, D., Barnett, B., Dent,
A.L., Craft, J., and Crotty, S. (2009). Bcl6 and Blimp-1 are reciprocal and
antagonistic regulators of T follicular helper cell differentiation. Science 325,
1006–1010.
Kang, Y.K., Andjelic, S., Binley, J.M., Crooks, E.T., Franti, M., Iyer, S.P.,
Donovan, G.P., Dey, A.K., Zhu, P., Roux, K.H., et al. (2009). Structural and
immunogenicity studies of a cleaved, stabilized envelope trimer derived from
subtype A HIV-1. Vaccine 27, 5120–5132.
Karlsson Hedestam, G.B., Fouchier, R.A., Phogat, S., Burton, D.R., Sodroski,
J., and Wyatt, R.T. (2008). The challenges of eliciting neutralizing antibodies to
HIV-1 and to influenza virus. Nat. Rev. Microbiol. 6, 143–155.
Klavinskis, L.S., Geckeler, R., and Oldstone, M.B. (1989). Cytotoxic T lympho-
cyte control of acute lymphocytic choriomeningitis virus infection: interferon
gamma, but not tumour necrosis factor alpha, displays antiviral activity in vivo.
J. Gen. Virol. 70, 3317–3325.
Klein, F., Gaebler, C., Mouquet, H., Sather, D.N., Lehmann, C., Scheid, J.F.,
Kraft, Z., Liu, Y., Pietzsch, J., Hurley, A., et al. (2012). Broad neutralization
by a combination of antibodies recognizing the CD4 binding site and a newconformational epitope on the HIV-1 envelope protein. J. Exp. Med. 209,
1469–1479.
Kong, L., and Sattentau, Q. (2012). Antigenicity and immunogenicity in HIV-1
antibody-based vaccine design. J. AIDS Clinic Res. S8. http://dx.doi.org/10.
4172/2155-6113.S8-003.
Kuate, S., Stahl-Hennig, C., Stoiber, H., Nchinda, G., Floto, A., Franz, M.,
Sauermann, U., Bredl, S., Deml, L., Ignatius, R., et al. (2006). Immunogenicity
and efficacy of immunodeficiency virus-like particles pseudotyped with the G
protein of vesicular stomatitis virus. Virology 351, 133–144.
Kulkarni, A.B., Collins, P.L., Bacik, I., Yewdell, J.W., Bennink, J.R., Crowe, J.E.,
Jr., and Murphy, B.R. (1995). Cytotoxic T cells specific for a single peptide on
the M2 protein of respiratory syncytial virus are the sole mediators of resis-
tance induced by immunization with M2 encoded by a recombinant vaccinia
virus. J. Virol. 69, 1261–1264.
Kumamoto, Y., Mattei, L.M., Sellers, S., Payne, G.W., and Iwasaki, A. (2011).
CD4+ T cells support cytotoxic T lymphocyte priming by controlling lymph
node input. Proc. Natl. Acad. Sci. USA 108, 8749–8754.
Kwong, P.D., and Wilson, I.A. (2009). HIV-1 and influenza antibodies: seeing
antigens in new ways. Nat. Immunol. 10, 573–578.
Kwong, P.D., Mascola, J.R., and Nabel, G.J. (2011). Rational design of
vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb.
Perspect. Med. 1, a007278. http://dx.doi.org/10.1101/cshperspect.a007278.
Kwong, P.D., Mascola, J.R., and Nabel, G.J. (2012). The changing face of HIV
vaccine research. J. Int. AIDS Soc. 15, 17407.
Lathey, J.L., Tsou, J., Brinker, K., Hsia, K., Meyer, W.A., 3rd, and Spector, S.A.
(1999). Lack of autologous neutralizing antibody to human immunodeficiency
virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-
infant transmission. J. Infect. Dis. 180, 344–350.
Legrand, N., Ploss, A., Balling, R., Becker, P.D., Borsotti, C., Brezillon, N.,
Debarry, J., de Jong, Y., Deng, H., Di Santo, J.P., et al. (2009). Humanized
mice for modeling human infectious disease: challenges, progress, and
outlook. Cell Host Microbe 6, 5–9.
Li, M., Gao, F., Mascola, J.R., Stamatatos, L., Polonis, V.R., Koutsoukos, M.,
Voss, G., Goepfert, P., Gilbert, P., Greene, K.M., et al. (2005). Human immuno-
deficiency virus type 1 env clones from acute and early subtype B infections for
standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol.
79, 10108–10125.
Li, Y., Svehla, K., Mathy, N.L., Voss, G., Mascola, J.R., and Wyatt, R. (2006).
Characterization of antibody responses elicited by human immunodeficiency
virus type 1 primary isolate trimeric and monomeric envelope glycoproteins
in selected adjuvants. J. Virol. 80, 1414–1426.
Li, Y., Migueles, S.A., Welcher, B., Svehla, K., Phogat, A., Louder,M.K.,Wu, X.,
Shaw, G.M., Connors, M., Wyatt, R.T., and Mascola, J.R. (2007). Broad HIV-1
neutralization mediated by CD4-binding site antibodies. Nat. Med. 13,
1032–1034.
Li, Y., Svehla, K., Louder, M.K., Wycuff, D., Phogat, S., Tang, M., Migueles,
S.A., Wu, X., Phogat, A., Shaw, G.M., et al. (2009). Analysis of neutralization
specificities in polyclonal sera derived from human immunodeficiency virus
type 1-infected individuals. J. Virol. 83, 1045–1059.
Lindqvist, M., van Lunzen, J., Soghoian, D.Z., Kuhl, B.D., Ranasinghe, S.,
Kranias, G., Flanders, M.D., Cutler, S., Yudanin, N., Muller, M.I., et al. (2012).
Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J.
Clin. Invest. 122, 3271–3280.
Liu, J., Bartesaghi, A., Borgnia, M.J., Sapiro, G., and Subramaniam, S. (2008).
Molecular architecture of native HIV-1 gp120 trimers. Nature 455, 109–113.
Liu, J., O’Brien, K.L., Lynch, D.M., Simmons, N.L., La Porte, A., Riggs, A.M.,
Abbink, P., Coffey, R.T., Grandpre, L.E., Seaman, M.S., et al. (2009). Immune
control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.
Nature 457, 87–91.
Luban, J. (2012). Innate immune sensing of HIV-1 by dendritic cells. Cell Host
Microbe 12, this issue, 408–418.
Mao, Y., Wang, L., Gu, C., Herschhorn, A., Xiang, S.H., Haim, H., Yang, X., and
Sodroski, J. (2012). Subunit organization of the membrane-bound HIV-1
envelope glycoprotein trimer. Nat. Struct. Mol. Biol. 19, 893–899.Cell Host & Microbe 12, October 18, 2012 ª2012 Elsevier Inc. 405
Cell Host & Microbe
PerspectiveMarsac, D., Loirat, D., Petit, C., Schwartz, O., and Michel, M.L. (2002).
Enhanced presentation of major histocompatibility complex class I-restricted
human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA
immunization with vectors coding for vesicular stomatitis virus glycoprotein-
pseudotyped HIV-1 Gag particles. J. Virol. 76, 7544–7553.
Mascola, J.R., and Montefiori, D.C. (2010). The role of antibodies in HIV
vaccines. Annu. Rev. Immunol. 28, 413–444.
McElrath, M.J., and Haynes, B.F. (2010). Induction of immunity to human
immunodeficiency virus type-1 by vaccination. Immunity 33, 542–554.
McLellan, J.S., Correia, B.E., Chen, M., Yang, Y., Graham, B.S., Schief, W.R.,
and Kwong, P.D. (2011). Design and characterization of epitope-scaffold
immunogens that present the motavizumab epitope from respiratory syncytial
virus. J. Mol. Biol. 409, 853–866.
Mikell, I., Sather, D.N., Kalams, S.A., Altfeld, M., Alter, G., and Stamatatos, L.
(2011). Characteristics of the earliest cross-neutralizing antibody response to
HIV-1. PLoS Pathog. 7, e1001251. http://dx.doi.org/10.1371/journal.ppat.
1001251.
Mizuochi, T., Spellman, M.W., Larkin, M., Solomon, J., Basa, L.J., and Feizi, T.
(1988). Carbohydrate structures of the human-immunodeficiency-virus (HIV)
recombinant envelope glycoprotein gp120 produced in Chinese-hamster
ovary cells. Biochem. J. 254, 599–603.
Moir, S., Malaspina, A., and Fauci, A.S. (2011). Prospects for an HIV vaccine:
leading B cells down the right path. Nat. Struct. Mol. Biol. 18, 1317–1321.
Moore, P.L., Crooks, E.T., Porter, L., Zhu, P., Cayanan, C.S., Grise, H.,
Corcoran, P., Zwick, M.B., Franti, M., Morris, L., et al. (2006). Nature of
nonfunctional envelope proteins on the surface of human immunodeficiency
virus type 1. J. Virol. 80, 2515–2528.
Moore, P.L., Gray, E.S., Sheward, D., Madiga, M., Ranchobe, N., Lai, Z.,
Honnen, W.J., Nonyane, M., Tumba, N., Hermanus, T., et al; CAPRISA 002
Study. (2011). Potent and broad neutralization of HIV-1 subtype C by plasma
antibodies targeting a quaternary epitope including residues in the V2 loop.
J. Virol. 85, 3128–3141.
Morris, L., Chen, X., Alam, M., Tomaras, G., Zhang, R., Marshall, D.J., Chen,
B., Parks, R., Foulger, A., Jaeger, F., et al. (2011). Isolation of a human anti-
HIV gp41 membrane proximal region neutralizing antibody by antigen-specific
single B cell sorting. PLoS ONE 6, e23532. http://dx.doi.org/10.1371/journal.
pone.0023532.
Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G., Ru¨ker,
F., and Katinger, H. (1993). A conserved neutralizing epitope on gp41 of human
immunodeficiency virus type 1. J. Virol. 67, 6642–6647.
Nurieva, R.I., Chung, Y., Martinez, G.J., Yang, X.O., Tanaka, S., Matskevitch,
T.D., Wang, Y.H., and Dong, C. (2009). Bcl6 mediates the development of T
follicular helper cells. Science 325, 1001–1005.
Ofek, G., Guenaga, F.J., Schief, W.R., Skinner, J., Baker, D., Wyatt, R., and
Kwong, P.D. (2010). Elicitation of structure-specific antibodies by epitope
scaffolds. Proc. Natl. Acad. Sci. USA 107, 17880–17887.
Overbaugh, J., and Morris, L. (2012). The antibody response against HIV-1.
Cold Spring Harb. Perspect. Med. 2, a007039.
Pantophlet, R., and Burton, D.R. (2006). GP120: target for neutralizing HIV-1
antibodies. Annu. Rev. Immunol. 24, 739–769.
Pantophlet, R., Wang, M., Aguilar-Sino, R.O., and Burton, D.R. (2009). The
human immunodeficiency virus type 1 envelope spike of primary viruses can
suppress antibody access to variable regions. J. Virol. 83, 1649–1659.
Parren, P.W., andBurton, D.R. (2001). The antiviral activity of antibodies in vitro
and in vivo. Adv. Immunol. 77, 195–262.
Pejchal, R., Doores, K.J., Walker, L.M., Khayat, R., Huang, P.S., Wang, S.K.,
Stanfield, R.L., Julien, J.P., Ramos, A., Crispin, M., et al. (2011). A potent
and broad neutralizing antibody recognizes and penetrates the HIV glycan
shield. Science 334, 1097–1103.
Petrovas, C., Yamamoto, T., Gerner, M.Y., Boswell, K.L., Wloka, K., Smith,
E.C., Ambrozak, D.R., Sandler, N.G., Timmer, K.J., Sun, X., et al. (2012).
CD4 T follicular helper cell dynamics during SIV infection. J. Clin. Invest.
122, 3281–3294.406 Cell Host & Microbe 12, October 18, 2012 ª2012 Elsevier Inc.Phogat, S., and Wyatt, R. (2007). Rational modifications of HIV-1 envelope
glycoproteins for immunogen design. Curr. Pharm. Des. 13, 213–227.
Pitisuttithum, P., Gilbert, P., Gurwith, M., Heyward, W., Martin, M., van
Griensven, F., Hu, D., Tappero, J.W., and Choopanya, K.; Bangkok Vaccine
Evaluation Group. (2006). Randomized, double-blind, placebo-controlled
efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among
injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661–1671.
Plotkin, S.A. (2008). Vaccine, Fifth Edition (Philadelphia: Elsevier Health
Sciences).
Plotkin, S.A. (2010). Correlates of protection induced by vaccination. Clin.
Vaccine Immunol. 17, 1055–1065.
Poignard, P., Moulard, M., Golez, E., Vivona, V., Franti, M., Venturini, S., Wang,
M., Parren, P.W., and Burton, D.R. (2003). Heterogeneity of envelope mole-
cules expressed on primary human immunodeficiency virus type 1 particles
as probed by the binding of neutralizing and nonneutralizing antibodies.
J. Virol. 77, 353–365.
Querec, T.D., Akondy, R.S., Lee, E.K., Cao, W., Nakaya, H.I., Teuwen, D.,
Pirani, A., Gernert, K., Deng, J., Marzolf, B., et al. (2009). Systems biology
approach predicts immunogenicity of the yellow fever vaccine in humans.
Nat. Immunol. 10, 116–125.
Raska, M., Takahashi, K., Czernekova, L., Zachova, K., Hall, S., Moldoveanu,
Z., Elliott, M.C., Wilson, L., Brown, R., Jancova, D., et al. (2010). Glycosylation
patterns of HIV-1 gp120 depend on the type of expressing cells and affect
antibody recognition. J. Biol. Chem. 285, 20860–20869.
Rathinam, C., Poueymirou, W.T., Rojas, J., Murphy, A.J., Valenzuela, D.M.,
Yancopoulos, G.D., Rongvaux, A., Eynon, E.E., Manz, M.G., and Flavell,
R.A. (2011). Efficient differentiation and function of human macrophages in
humanized CSF-1 mice. Blood 118, 3119–3128.
Roben, P., Moore, J.P., Thali, M., Sodroski, J., Barbas, C.F., 3rd, and Burton,
D.R. (1994). Recognition properties of a panel of human recombinant Fab frag-
ments to the CD4 binding site of gp120 that showdiffering abilities to neutralize
human immunodeficiency virus type 1. J. Virol. 68, 4821–4828.
Rolf, J., Bell, S.E., Kovesdi, D., Janas, M.L., Soond, D.R., Webb, L.M., Santi-
nelli, S., Saunders, T., Hebeis, B., Killeen, N., et al. (2010). Phosphoinositide
3-kinase activity in T cells regulates the magnitude of the germinal center reac-
tion. J. Immunol. 185, 4042–4052.
Roozendaal, R., Mempel, T.R., Pitcher, L.A., Gonzalez, S.F., Verschoor, A.,
Mebius, R.E., von Andrian, U.H., and Carroll, M.C. (2009). Conduits mediate
transport of low-molecular-weight antigen to lymph node follicles. Immunity
30, 264–276.
Salzwedel, K., West, J.T., and Hunter, E. (1999). A conserved tryptophan-rich
motif in the membrane-proximal region of the human immunodeficiency virus
type 1 gp41 ectodomain is important for Env-mediated fusion and virus infec-
tivity. J. Virol. 73, 2469–2480.
Sather, D.N., Armann, J., Ching, L.K., Mavrantoni, A., Sellhorn, G., Caldwell,
Z., Yu, X., Wood, B., Self, S., Kalams, S., et al. (2009). Factors associated
with the development of cross-reactive neutralizing antibodies during HIV-1
infection. J. Virol. 83, 757–769.
Sattentau, Q.J., andMoore, J.P. (1995). Human immunodeficiency virus type 1
neutralization is determined by epitope exposure on the gp120 oligomer. J.
Exp. Med. 182, 185–196.
Scarlatti, G., Albert, J., Rossi, P., Hodara, V., Biraghi, P., Muggiasca, L., and
Fenyo¨, E.M. (1993a). Mother-to-child transmission of human immunodefi-
ciency virus type 1: correlation with neutralizing antibodies against primary
isolates. J. Infect. Dis. 168, 207–210.
Scarlatti, G., Leitner, T., Hodara, V., Halapi, E., Rossi, P., Albert, J., and Fenyo¨,
E.M. (1993b). Neutralizing antibodies and viral characteristics in mother-to-
child transmission of HIV-1. AIDS 7 (Suppl 2 ), S45–S48.
Scheid, J.F., Mouquet, H., Feldhahn, N., Seaman, M.S., Velinzon, K., Pietzsch,
J., Ott, R.G., Anthony, R.M., Zebroski, H., Hurley, A., et al. (2009). Broad diver-
sity of neutralizing antibodies isolated from memory B cells in HIV-infected
individuals. Nature 458, 636–640.
Scheid, J.F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T.Y.,
Pietzsch, J., Fenyo, D., Abadir, A., Velinzon, K., et al. (2011). Sequence and
structural convergence of broad and potent HIV antibodies that mimic CD4
binding. Science 333, 1633–1637.
Cell Host & Microbe
PerspectiveSchief, W.R., Ban, Y.E., and Stamatatos, L. (2009). Challenges for structure-
based HIV vaccine design. Curr. Opin. HIV AIDS 4, 431–440.
Sette, A., Moutaftsi, M., Moyron-Quiroz, J., McCausland, M.M., Davies, D.H.,
Johnston, R.J., Peters, B., Rafii-El-Idrissi Benhnia, M., Hoffmann, J., Su, H.P.,
et al. (2008). Selective CD4+ T cell help for antibody responses to a large viral
pathogen: deterministic linkage of specificities. Immunity 28, 847–858.
Simek, M.D., Rida, W., Priddy, F.H., Pung, P., Carrow, E., Laufer, D.S.,
Lehrman, J.K., Boaz, M., Tarragona-Fiol, T., Miiro, G., et al. (2009). Human
immunodeficiency virus type 1 elite neutralizers: individuals with broad and
potent neutralizing activity identified by using a high-throughput neutralization
assay together with an analytical selection algorithm. J. Virol. 83, 7337–7348.
Smith, D.M., Strain, M.C., Frost, S.D., Pillai, S.K., Wong, J.K., Wrin, T., Liu, Y.,
Petropolous, C.J., Daar, E.S., Little, S.J., and Richman, D.D. (2006). Lack of
neutralizing antibody response to HIV-1 predisposes to superinfection.
Virology 355, 1–5.
Soghoian, D.Z., Jessen, H., Flanders, M., Sierra-Davidson, K., Cutler, S.,
Pertel, T., Ranasinghe, S., Lindqvist, M., Davis, I., Lane, K., et al. (2012).
HIV-specific cytolytic CD4+ T-cell responses during acute HIV-1 infection
predict disease outcome. Sci. Transl. Med. 4, 123ra125. http://dx.doi.org/
10.1126/scitranslmed.3003165.
Stamatatos, L., Morris, L., Burton, D.R., and Mascola, J.R. (2009). Neutralizing
antibodies generated during natural HIV-1 infection: good news for an HIV-1
vaccine? Nat. Med. 15, 866–870.
Tiller, T., Meffre, E., Yurasov, S., Tsuiji, M., Nussenzweig, M.C., and
Wardemann, H. (2008). Efficient generation of monoclonal antibodies from
single human B cells by single cell RT-PCR and expression vector cloning.
J. Immunol. Methods 329, 112–124.
Ulmer, J.B., Donnelly, J.J., Parker, S.E., Rhodes, G.H., Felgner, P.L., Dwarki,
V.J., Gromkowski, S.H., Deck, R.R., DeWitt, C.M., Friedman, A., et al.
(1993). Heterologous protection against influenza by injection of DNA encod-
ing a viral protein. Science 259, 1745–1749.
van Gils, M.J., Euler, Z., Schweighardt, B., Wrin, T., and Schuitemaker, H.
(2009). Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-
infected patients with rapid or slow disease progression. AIDS 23, 2405–2414.
Verkoczy, L., Kelsoe, G., Moody, M.A., and Haynes, B.F. (2011). Role of
immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.
Curr. Opin. Immunol. 23, 383–390.
Victora, G.D., Schwickert, T.A., Fooksman, D.R., Kamphorst, A.O., Meyer-
Hermann, M., Dustin, M.L., and Nussenzweig, M.C. (2010). Germinal center
dynamics revealed by multiphoton microscopy with a photoactivatable
fluorescent reporter. Cell 143, 592–605.
Walker, B.D., and Burton, D.R. (2008). Toward an AIDS vaccine. Science 320,
760–764.
Walker, L.M., and Burton, D.R. (2010). Rational antibody-based HIV-1 vaccine
design: current approaches and future directions. Curr. Opin. Immunol. 22,
358–366.
Walker, L.M., Phogat, S.K., Chan-Hui, P.Y., Wagner, D., Phung, P., Goss, J.L.,
Wrin, T., Simek, M.D., Fling, S., Mitcham, J.L., et al; Protocol G Principal Inves-
tigators. (2009). Broad and potent neutralizing antibodies from an African
donor reveal a new HIV-1 vaccine target. Science 326, 285–289.
Walker, L.M., Simek, M.D., Priddy, F., Gach, J.S., Wagner, D., Zwick, M.B.,
Phogat, S.K., Poignard, P., and Burton, D.R. (2010). A limited number of anti-
body specificities mediate broad and potent serum neutralization in selected
HIV-1 infected individuals. PLoS Pathog. 6, e1001028. http://dx.doi.org/10.
1371/journal.ppat.1001028.
Walker, L.M., Huber, M., Doores, K.J., Falkowska, E., Pejchal, R., Julien, J.P.,
Wang, S.K., Ramos, A., Chan-Hui, P.Y., Moyle, M., et al; Protocol G Principal
Investigators. (2011a). Broad neutralization coverage of HIV by multiple highly
potent antibodies. Nature 477, 466–470.
Walker, L.M., Sok, D., Nishimura, Y., Pejchal, R., Ramos, A., Simek, M.D.,
Geng, Y., Wilson, I.A., Poignard, P., Martin, M.A., et al. (2011b). Rapid devel-
opment of glycan-specific, broad and potent anti-HIV-1 gp120 neutralizingantibodies in a SHIV- infected macaque. Proc. Natl. Acad. Sci. USA 108,
20125–20129.
Wallace, A., and Stamatatos, L. (2009). Introduction of exogenous epitopes in
the variable regions of the human immunodeficiency virus type 1 envelope
glycoprotein: effect on viral infectivity and the neutralization phenotype.
J. Virol. 83, 7883–7893.
Watkins, D.I. (2008). The hope for anHIV vaccine based on induction of CD8+ T
lymphocytes—a review. Mem. Inst. Oswaldo Cruz 103, 119–129.
West, A.P., Jr., Diskin, R., Nussenzweig, M.C., and Bjorkman, P.J. (2012).
Structural basis for germ-line gene usage of a potent class of antibodies
targeting the CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA
109, E2083–E2090.
Wheeler, L.A., Trifonova, R., Vrbanac, V., Basar, E., McKernan, S., Xu, Z.,
Seung, E., Deruaz, M., Dudek, T., Einarsson, J.I., et al. (2011). Inhibition of
HIV transmission in human cervicovaginal explants and humanizedmice using
CD4 aptamer-siRNA chimeras. J. Clin. Invest. 121, 2401–2412.
Wu, X., Yang, Z.Y., Li, Y., Hogerkorp, C.M., Schief, W.R., Seaman, M.S., Zhou,
T., Schmidt, S.D.,Wu, L., Xu, L., et al. (2010). Rational design of envelope iden-
tifies broadly neutralizing human monoclonal antibodies to HIV-1. Science
329, 856–861.
Wu, X., Zhou, T., Zhu, J., Zhang, B., Georgiev, I., Wang, C., Chen, X., Longo,
N.S., Louder, M., McKee, K., et al; NISC Comparative Sequencing Program.
(2011). Focused evolution of HIV-1 neutralizing antibodies revealed by struc-
tures and deep sequencing. Science 333, 1593–1602.
Wu, X., Lynch, R., Yang, Z., Tran, L., Perfetto, S., Longo, N.S., O’Dell, S.,
McKee, K., Doria-Rose, N., Connors, M., et al. (2012). Different gene compo-
sition of broadly neutralizing antibodies to the conserved CD4-binding site of
HIV-1 envelope. In Keystone Symposia: HIV Vaccines (X5) (Colorado:
Keystone), p. 361.
Wyatt, R., and Sodroski, J. (1998). The HIV-1 envelope glycoproteins:
fusogens, antigens, and immunogens. Science 280, 1884–1888.
Xiao, X., Chen, W., Feng, Y., Zhu, Z., Prabakaran, P., Wang, Y., Zhang, M.Y.,
Longo, N.S., and Dimitrov, D.S. (2009). Germline-like predecessors of broadly
neutralizing antibodies lack measurable binding to HIV-1 envelope glycopro-
teins: implications for evasion of immune responses and design of vaccine
immunogens. Biochem. Biophys. Res. Commun. 390, 404–409.
Yang, X., Lipchina, I., Cocklin, S., Chaiken, I., and Sodroski, J. (2006). Antibody
binding is a dominant determinant of the efficiency of human immunodefi-
ciency virus type 1 neutralization. J. Virol. 80, 11404–11408.
Yu, D., Rao, S., Tsai, L.M., Lee, S.K., He, Y., Sutcliffe, E.L., Srivastava, M.,
Linterman, M., Zheng, L., Simpson, N., et al. (2009). The transcriptional
repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity
31, 457–468.
Zhou, T., Xu, L., Dey, B., Hessell, A.J., Van Ryk, D., Xiang, S.H., Yang, X.,
Zhang, M.Y., Zwick, M.B., Arthos, J., et al. (2007). Structural definition of
a conserved neutralization epitope on HIV-1 gp120. Nature 445, 732–737.
Zhou, T., Georgiev, I., Wu, X., Yang, Z.Y., Dai, K., Finzi, A., Kwon, Y.D., Scheid,
J.F., Shi, W., Xu, L., et al. (2010). Structural basis for broad and potent neutral-
ization of HIV-1 by antibody VRC01. Science 329, 811–817.
Zhu, X., Borchers, C., Bienstock, R.J., and Tomer, K.B. (2000). Mass spectro-
metric characterization of the glycosylation pattern of HIV-gp120 expressed in
CHO cells. Biochemistry 39, 11194–11204.
Zhu, Z., Qin, H.R., Chen, W., Zhao, Q., Shen, X., Schutte, R., Wang, Y., Ofek,
G., Streaker, E., Prabakaran, P., et al. (2011). Cross-reactive HIV-1-
neutralizing human monoclonal antibodies identified from a patient with 2F5-
like antibodies. J. Virol. 85, 11401–11408.
Zwick, M.B., Labrijn, A.F., Wang, M., Spenlehauer, C., Saphire, E.O., Binley,
J.M., Moore, J.P., Stiegler, G., Katinger, H., Burton, D.R., and Parren, P.W.
(2001). Broadly neutralizing antibodies targeted to the membrane-proximal
external region of human immunodeficiency virus type 1 glycoprotein gp41.
J. Virol. 75, 10892–10905.Cell Host & Microbe 12, October 18, 2012 ª2012 Elsevier Inc. 407
